Nielsen DL - Search Results

1

ABCG2 Protein Levels and Association to Response to First-Line Irinotecan-Based Therapy for Patients with Metastatic Colorectal Cancer.

Palshof JA, Cederbye CN, Høgdall EVS, Poulsen TS, Linnemann D, Nygaard SB, Stenvang J, Christensen IJ, Jensen BV, Pfeiffer P, Brünner N, Yilmaz M, Viuff BM, Nielsen DL. Palshof JA, et al. Among authors: nielsen dl. Int J Mol Sci. 2020 Jul 16;21(14):5027. doi: 10.3390/ijms21145027. Int J Mol Sci. 2020. PMID: 32708825 Free PMC article.

2

Angiotensin converting enzyme inhibitors for cancer treatment?

Lindberg H, Nielsen D, Jensen BV, Eriksen J, Skovsgaard T. Lindberg H, et al. Acta Oncol. 2004;43(2):142-52. doi: 10.1080/02841860310022346. Acta Oncol. 2004. PMID: 15163162 Review.

3

Serum YKL-40, a new prognostic biomarker in cancer patients?

Johansen JS, Jensen BV, Roslind A, Nielsen D, Price PA. Johansen JS, et al. Cancer Epidemiol Biomarkers Prev. 2006 Feb;15(2):194-202. doi: 10.1158/1055-9965.EPI-05-0011. Cancer Epidemiol Biomarkers Prev. 2006. PMID: 16492905 Review.

4

Anthracycline-induced chronic cardiotoxicity and heart failure.

Appel JM, Nielsen D, Zerahn B, Jensen BV, Skagen K. Appel JM, et al. Acta Oncol. 2007;46(5):576-80. doi: 10.1080/02841860601156165. Acta Oncol. 2007. PMID: 17562433 Review.

5

Cetuximab and irinotecan as third line therapy in patients with advanced colorectal cancer after failure of irinotecan, oxaliplatin and 5-fluorouracil.

Pfeiffer P, Nielsen D, Yilmaz M, Iversen A, Vejlø C, Jensen BV. Pfeiffer P, et al. Acta Oncol. 2007;46(5):697-701. doi: 10.1080/02841860601009455. Acta Oncol. 2007. PMID: 17562448

6

Addition of sunitinib to cetuximab and irinotecan in patients with heavily pre-treated advanced colorectal cancer.

Qvortrup C, Jensen BV, Jorgensen TL, Nielsen D, Bjerregaard JK, Pfeiffer P. Qvortrup C, et al. Acta Oncol. 2010 Aug;49(6):833-6. doi: 10.3109/0284186X.2010.482104. Acta Oncol. 2010. PMID: 20615171

7

Bevacizumab in combination with cetuximab and irinotecan after failure of cetuximab and irinotecan in patients with metastatic colorectal cancer.

Larsen FO, Pfeiffer P, Nielsen D, Skougaard K, Qvortrup C, Vistisen K, Fromm AL, Jørgensen TL, Bjerregaard JK, Hoegdall E, Jensen BV. Larsen FO, et al. Acta Oncol. 2011 May;50(4):574-7. doi: 10.3109/0284186X.2010.546369. Acta Oncol. 2011. PMID: 21529301

8

Observer variability in a phase II trial - assessing consistency in RECIST application.

Skougaard K, McCullagh MJ, Nielsen D, Hendel HW, Jensen BV, Johannesen HH. Skougaard K, et al. Acta Oncol. 2012 Jul;51(6):774-80. doi: 10.3109/0284186X.2012.667149. Epub 2012 Mar 21. Acta Oncol. 2012. PMID: 22432439 Clinical Trial.

9

Comparison of EORTC criteria and PERCIST for PET/CT response evaluation of patients with metastatic colorectal cancer treated with irinotecan and cetuximab.

Skougaard K, Nielsen D, Jensen BV, Hendel HW. Skougaard K, et al. J Nucl Med. 2013 Jul;54(7):1026-31. doi: 10.2967/jnumed.112.111757. Epub 2013 Apr 9. J Nucl Med. 2013. PMID: 23572497 Free article. Clinical Trial.

10

Biomarker-guided repurposing of chemotherapeutic drugs for cancer therapy: a novel strategy in drug development.

Stenvang J, Kümler I, Nygård SB, Smith DH, Nielsen D, Brünner N, Moreira JM. Stenvang J, et al. Front Oncol. 2013 Dec 25;3:313. doi: 10.3389/fonc.2013.00313. Front Oncol. 2013. PMID: 24400218 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

202 results

Search Page